Grifols strengthens its presence in the Chinese market
The Catalan pharmaceutical company Grífols, third worldwide company in plasma derivatives, has signed a cooperation agreement with the Shanghai Blood Bank. The agreement, which strengthens the presence of the Catalan company in China, promotes blood genotyping research. The Chinese institution will use the Grifols’ genetic test BLOODchip in transfusion compatibility studies. Shanghai Blood Bank serves over 20 million people and receives more than 300.000 donations per year. In 2011, Grifols sales in China grew by 30%.
May 22, 2012 03:33 PM